Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
13.00    0.50 (4.00%)
Bid:
12.50
Ask:
13.50
Spread: 1.00 (8.00%)
Market Cap: £16.25m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Acquisition

4 Jun 2007 07:02

Fabian Romania Property Fund Ltd04 June 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or the "Fund") Fabian Romania announces the purchase of a €4.9 million office building inBucharest Fabian Romania has reached agreement to purchase the Evocenter office buildingin the Pipera / Voluntari district of Bucharest for a forecast yield of 9 percent.. The Evocenter will be the Fund's fourth office building in Bucharest. The fund had initially proposed to purchase the building empty, thereby takingthe letting risk. However, during the due diligence process, the Adama Groupfrom Israel, the developer, signed a lease taking half of the available space.The building will be completed in summer 2007 to a Class A standard andcomprises 3,000m2 of net lettable area, 18 covered car parking spaces andancillary parking close by. It is arranged over seven levels, basement, groundfloor, mezzanine and four office floors. Rents that will be achieved for the building are forecast to be €12 sqm/monthfor ground, mezzanine and floors one to four, €65 sqm/month for parking and €7sqm/month for storage. Once all space is fully let, the yield is forecast to be9 per cent.. The Fund will meet the consideration of €4.9 million from its own resources.Debt drawdown is anticipated to be during the third quarter 2007 which willreduce the ongoing equity requirement to around €1 million. Commenting on the transaction, Mark Holdsworth, Managing Director of FabianCapital, the Investment Advisor to the Fund said: "We are delighted that the Fund has sealed agreement to buy this commercialoffice building. Based on our experience and given the ongoing shortage ofoffice space in Bucharest, we believe it is in the Fund's interest to agree totake the letting risk for the building in return for sealing a more attractiveprice. By having the Adama Group, as both anchor tenant and vendor, we consider we haveensured a quality product through the alignment of interests. We are confidentof letting the rest of the building out to multinational tenants in the nearfuture." Following the acquisition of 40-44 Banu Antonache in January 2006, the purchaseof the Adama building will be the second occasion the fund has taken the lettingrisk. The lead advisers on the transaction were DTZ (property agent), WSP (technicaladvisers) and Tuca Zbarcea Asociatii (legal adviser). For Comments: Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLPJames Lewis +44 20 7936 3000 Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jun 20267:00 amRNSExercise of options and total voting rights
11th May 20263:06 pmRNSHolding(s) in Company
11th May 202611:05 amRNSGrant of patent in Japan
5th May 20267:00 amRNSYear-end trading statement
30th Mar 20267:00 amRNSAntibody IP transfer agreement
17th Feb 202611:42 amRNSDirector/PDMR Shareholding
4th Feb 20263:27 pmRNSHolding(s) in Company
2nd Feb 202611:33 amRNSHolding(s) in Company
30th Jan 20265:00 pmRNSTotal Voting Rights
27th Jan 20267:05 amRNSIssue of Director Shares
27th Jan 20267:00 amRNSPlacing and Subscription to raise approx £1.4m
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
16th Dec 202511:04 amRNSLaunch of OptiMAL platform
11th Dec 20257:00 amRNS-RMammalian Display video
25th Nov 202512:11 pmRNSHolding(s) in Company
24th Nov 20257:00 amRNSHalf-year Financial Report
21st Nov 20257:00 amRNSNotice of Results
13th Nov 20257:00 amRNS-ROptiMAL Library video
3rd Nov 20257:00 amRNSOptiMAL® R&D Update
27th Oct 20253:38 pmRNSHolding(s) in Company
16th Oct 20251:31 pmRNSResult of AGM
16th Oct 20257:00 amRNSAGM statement and H1 trading update
8th Oct 20257:00 amRNSContract win
19th Sep 202512:58 pmRNSPosting of Annual Report & Notice of AGM
17th Sep 20257:00 amRNSOptiMAL R&D Update
8th Sep 20257:00 amRNS-RBelfast investor presentation
4th Sep 20257:00 amRNSFinal Results
28th Aug 20257:00 amRNSContract Win
27th Aug 20257:00 amRNSContract wins with existing client
26th Aug 20257:00 amRNS-RInvestor presentations
5th Aug 20257:00 amRNSGrant of U.S. Patent for OptiMAL
24th Jul 202510:56 amRNSIssue Notification: US Patent Update
11th Jul 20257:00 amRNSDirector/PDMR Shareholding
2nd Jun 20257:00 amRNSTotal Voting Rights
22nd May 20252:33 pmRNSUpdate on U.S. Patent for OptiMAL®
8th May 20257:00 amRNS-RInvestor presentation
7th May 20257:00 amRNSIssue of shares to non-executive directors
6th May 202510:53 amRNSDirector/PDMR Shareholding
6th May 202510:38 amRNSHolding(s) in Company
6th May 20257:00 amRNSTrading update
30th Apr 20255:00 pmRNSTotal Voting Rights
24th Apr 20257:00 amRNSApproval of grant funding
11th Apr 202510:40 amRNSHolding(s) in Company
10th Apr 202512:47 pmRNSHolding(s) in Company
7th Apr 202512:35 pmRNSResult of General Meeting
31st Mar 20255:00 pmRNSTotal Voting Rights
24th Mar 20254:38 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSPlacing to raise approximately £1.17 million
27th Feb 20257:00 amRNSContract win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.